Table 1 Discussion questions for the Qatar Oncology Health Economics Expert Panel (Q-OHEP) roundtable discussion, held on 30 November 2021
Domain | Questions |
|---|---|
Regulatory | • What are the oncology regulatory challenges with the current approval process? • How can we accelerate effective registration and use of oncology/hematology medications in Qatar? • Is a preliminary approval pathway in place? • Regarding clinical trials, what are the main challenges of these processes/protocols? |
Procurement | • What procurement issues do you or your institution experience in terms of accessibility to oncology medications? • What are the current challenges to fair access to oncology/hematology medications? • What are the available value-based options in Qatar, and what other models might be adopted? |
Treatment | • What are the challenges in applying/adopting national/international guidelines? • What are the key barriers you see for the use of new treatments in Qatar? • What are the current major treatment burdens for patients? |
Patients | • What are the systemic barriers to patient involvement in medication management or clinical trials? • How can we raise awareness among patients about involvement or participation in clinical trials? • Can you share a story that highlights an aspect relevant to accelerating access to medications? |